← Back to Search

LY3556050 + Metformin + Iohexol for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose on day 1 through 13 days postdose

Awards & highlights

Study Summary

The main purpose of this study is to evaluate how much Metformin gets into the bloodstream and how long the body takes to get rid of it when it is administered orally in combination with LY3556050 in healthy participants. Iohexol will be administered to evaluate kidney function. Each enrolled participant will remain in the study for up to 7 weeks including the screening period.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose on day 1 through 13 days postdose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose on day 1 through 13 days postdose

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 through 13 days postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Metformin

Trial Design

1Treatment groups

Experimental Treatment

Group I: LY3556050 + Metformin + IohexolExperimental Treatment3 Interventions

LY3556050 administered orally in combination with metformin given orally and iohexol given intravenously (IV).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Iohexol

2016

Completed Phase 4

~1920

Metformin

2006

Completed Phase 4

~2430

LY3556050

2021

Completed Phase 2

~520

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,617 Previous Clinical Trials

3,201,182 Total Patients Enrolled

Study DirectorEli Lilly and Company

1,346 Previous Clinical Trials

405,376 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential risks could be associated with the combination of LY3556050, Metformin and Iohexol?

"As this is a Phase 1 trial, with limited data for safety and efficacy, our team at Power estimated the risk to be low (1) on the scale of 1-3."

Answered by AI

What type of individuals are best suited for the current trial?

"This clinical trial is presently recruiting 18 healthy individuals aged 21 to 70. These volunteers must meet the following criteria in order to be considered: a bodyweight of 50 kg or more, BMI between 18.5-35 kg/m², medically certified health status, acceptable ECG results at screening; male participants required to use contraception while female participants whose reproductive abilities have not been impaired are also mandated to utilize birth control measures."

Answered by AI

Are individuals younger than 35 years of age admissible to this clinical trial?

"This study has set 21 to 70 years old as the age range for prospective participants. 50 studies are available on those below 18, while 372 research projects exist specifically targeting individuals 65 and above."

Answered by AI

Is enrolment for this experiment still available to the public?

"Unfortunately, this medical research is not currently recruiting. Though the trial was posted on November 14th 2022 and last updated on November 22nd 2022, 840 other studies are presently enrolling candidates."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Effect of LY3556050 on Metformin in Healthy Participants

2022. "A Study of Effect of LY3556050 on Metformin in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05615467.